drugset / Trial / NCT01251250

Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia

NCT01251250

Phase 1 Withdrawn Roswell Park Cancer Institute
Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Azadirachta indica may be an effective treatment for chronic lymphocytic leukemia. PURPOSE: This phase I trial is studying the side effects and best dose of Azadirachta indica in treating patients with chronic lymphocytic leukemia.

Timeline

Start
2010-12
Primary completion
2011-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Azadirachta Indica Traditional medicine (herbal / TCM) Oral